 |
Sarbani Bhaduri, M.D., Joins Acologix as Vice President, Medical Affairs
Hayward, CA – September 12, 2005 – Acologix, Inc. a
privately held biopharmaceutical company, today announced the appointment
of Sarbani Bhaduri, M.D. as its Vice President of Medical Affairs.
As a board certified nephrologist and with her experiences in early
to late stage clinical development, Dr. Bhaduri brings substantial
expertise in therapeutic product development for osteo-renal diseases.
Prior to joining Acologix, Dr. Bhaduri was the Nephrology Franchise
Associate Medical Director for Ortho Biotech, a subsidiary company
of Johnson and Johnson. At Ortho Biotech, Dr. Bhaduri was responsible
for Phase II, III, and IV clinical development using Epoetin alfa.
Dr. Bhaduri was part of the leadership team on the Phase I and II
clinical research investigating BMP-7, a bone morphogenetic protein
which may be useful in the prevention of kidney fibrosis.
Prior to joining Ortho Biotech, Dr. Bhaduri served as the Division
Head of Nephrology and Medical Director of Kidney/Pancreas Transplantation
at Scripps Clinic and Research Institute. Prior to joining Scripps,
Dr. Bhaduri was an Assistant Professor of Internal Medicine at the
University of California San Francisco and Davis for a total of
five years. Dr. Bhaduri received her B.S. from University of Texas
at El Paso and her M.D. at Texas Tech University, School of Medicine.
Dr. Bhaduri has also published numerous papers in the field of
anemia associated with chronic kidney disease, and kidney transplantation
as related to transplant sensitization and tolerance.
“We are thrilled to have Dr. Bhaduri join our team,”
said Yoshi Kumagai, President and CEO of Acologix. He added, “We
found that Dr. Bhaduri was not only a highly experienced clinician
but also an excellent scientist who had a profound understanding
of osteo-renal physiology. With Acologix now entering middle to
late stage clinical development for several of our development products,
Dr. Bhaduri’s addition to the team completes our in-house
product development capabilities for the foreseeable future.”
About Acologix, Inc.
Acologix strives to improve patients’ lives by developing
and commercializing innovative biopharmaceuticals targeting “osteo-renal”
(bone and kidney) diseases. Acologix’s substantial expertise
in identifying and developing therapeutics with unique mechanisms
of action (such as mineral metabolism sciences) is key to solving
major kidney and bone health problems. Chronic kidney failure, renal
osteodystrophy, orthopedics, periodontal disease, general dentistry
and oral care represent significant underserved medical needs. Acologix
is unique in its focus on these rapidly growing health care problems.
Acologix has recently announced the partnership with Toray Industries,
Inc. of Japan on the development and commercialization of AC-820,
an anti-puritic agent for the treatment of uremic pruritus in dialysis
patients. Pivotal Phase III clinical studies are expected to start
in Europe and the US in late 2005 and 2006, respectively. Acologix’s
leading skeletal tissue regenerating compound, AC-100 (Dentonin®)
is currently undergoing two Phase II clinical studies in Europe
and the United States for the repair of periodontal defects and
in dental restorations, respectively. Acologix is also developing
Phosphatonin to treat hyperphosphatemia and its subsequent clinical
problems in chronic kidney disease.
This press release contains “forward-looking” statements.
These statements involve risks and uncertainties, which may cause
results to differ materially from those set forth in the statements.
The forward-looking statements include statements regarding product
development and cannot be guaranteed. Acologix undertakes no obligation
to publicly update any forward-looking statement, whether as a result
of new information, future events, or otherwise. Forward-looking
statements in this press release should be evaluated together with
the many uncertainties that affect Acologix’s business.
Company Contact
Yoshi Kumagai
President and CEO
Phone: 510.512.7200
Fax: 510.786.1116
ir@acologix.com
| |
|
| |
|
